[Objective] To observe the dynamic changes of circulating immune complex (CIC) in monkeys infected by simian immunodeficiency virus (SIV). [Methods] Agglutination test of complement-sensitized yeast cell was used to determine the serum CIC level in 30 cases of monkeys, which were infected with SIVmac251 and sampled in different time-points after infection. Sixty-eight cases of normal monkeys were also examined as controls. [Results] After SIV infection, CIC can't be detected in all 30 monkeys until the 4th week, the total positive rate being 30% . In the 8th week, CIC were detected in 46.7% of these monkeys and then declined gradually in the following 12 weeks. Since the 20th week, the CIC in these monkeys maintained lower liter and lower positive rate which was close to that of the normal monkeys (about 10%). [Conclusion] CIC appeared and increased during the primary SIV infection and declined accompanying with the virus clearance from the circulalion. The formation of CIC may not benefit to the control of virus replication and the induction of anti-virus immunity; CIC has a role in the pathogenesis after SIV infection.

Objective To make the cost-effectiveness analysis of pembrolizumab and platinum chemotherapy as the first-line treatment for advanced non-small cell lung cancer （NSCLC） in the population with tumor proportion score （TPS） ≥ 1% of PD-L1, and provide some reference for the clinical use and future price negotiation of pembrolizumab. Methods Based on Pubmed database, the published RCT literatures of pembrolizumab were analyzed, and the survival data were extracted, combined with the treatment plan of a tertiary hospital, the Markov model were established to simulate the cost and health effectiveness of patients for twenty years, and the stability of the model was tested by one-way sensitivity analysis and probability sensitivity analysis. Results Twenty years later, the cost-effectiveness ratio of pembrolizumab group and chemotherapy group was ￥58 517.60/quality adjusted life month (QALM) and ￥41 213.08/QALM. Compared with the chemotherapy group, the incremental cost effective ratio (ICER) was ￥104 485.36/QALM. Conclusion When the willingness to pay （WTP） value was ￥30 902/QALM, the pembrolizumab therapy was not more cost-effective advantages than platinum chemotherapy, and the sensitivity analysis showed that the results of the model were relatively stable.